Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer

Abstract

SummaryObjective. To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy. Methods. Twenty mCRC patients treated at Affiliated Cancer Hospital of Shanxi Medical University from March 2017 to March 2019 were included according to the enrolment criteria. They provided informed consent and were treated with apatinib combined with FOLFIRI according to the scheduled regimen until disease progression or unacceptable toxicity occurred. The primary endpoint was OS. The secondary endpoints included PFS, ORR, DCRand safety. OS and PFS were calculated using Kaplan–Meier curves. Univariate and multivariate Cox regression analyses were used to evaluate independent prognostic factors of OS and PFS. R was used to determine cut-off values for biochemical indicators. Forest maps were drawn for Cox univariate results and the relationships between NLR and ECOG, which were significant in univariate analysis, and OS were represented by Kaplan–Meier curves. Results. The median OS and PFS were 16.135 months (95% CI: 9.211–22.929) and 6 months (95% CI: 5.425–6.525). Multivariate Cox analysis showed that NLR and CEA were independent prognostic factors. The most common grade 3–4 adverse events were hypertension, diarrhoea, increased alkaline phosphatase, decreased leukocytes and decreased neutrophils. Conclusion. Apatinib combined with FOLFIRI for the first-line treatment of advanced unresectable mCRC showed good efficacy and safety. The baseline NLR was predictive of efficacy, and a low baseline NLR (HR: 0.2895, P = 0.0084) was associated with improved OS.Clinical Research Registration Number: ChiCTR1800015308.

Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies

“…Thus it was approved by the National Medical Products Administration (NMPA) of China in 2014 as an alternative anti-neoplastic drug available for patients with advanced gastric cancer or gastroesophageal junction (GEJ) carcinoma (9). Furthermore, Apatinib exhibits promising anti-tumor activities in various tumors, including hepatocellular carcinoma, breast cancer, and non-small-cell lung cancer (10)(11)(12). Additionally, Apatinib could sensitize resistant tumor cells to chemotherapy drugs meanwhile reverse the multiple drug resistance (MDR) caused by ATPbinding cassette transporters proteins (13).…”

Efficacy and safety of tyrosine kinase inhibitors for advanced metastatic thyroid cancer: A systematic review and network meta-analysis of randomized controlled trials

“…[28] In previous studies, apatinib was shown to have an effect on human patients who had received chemotherapy for thyroid cancer and other advanced cancers, such as gastric cancer (6.5 vs 4.7 months, P = .0149), liver cancer, colorectal cancer, and breast cancer. [29][30][31][32] It can effectively exert antitumor effects. Previous clinical studies have shown that apatinib is a viable treatment option for advanced thyroid cancer with significant efficacy in ORR, PFS, and OS, and a good safety profile.…”

Thymoquinone Enhances the Antitumor Activity of Apatinib Against Gastrointestinal Tumors Through the STAT3 Pathway

“…APA has been approved as an antineoplastic drug for advanced GC or gastroesophageal junction (GEJ) cancer in China [7]. Additionally, APA exhibits excellent anti-tumor activity in HCC [8], breast cancer [9], and CRC [10].…”